numares’ Novel Multi-marker Kidney Function Testing Shows Promising Results in US Validation Study
numares today announced that its novel multi-marker approach for the accurate assessment of glomerular filtration rate (GFR) shows promising results in a US based clinical validation study. Using serum, GFRNMR evaluates a metabolite constellation of three metabolites combined with Cystatin C, age and sex. Compared to existing serum-based GFR methods, this multi-marker algorithm more accurately reflects gold-standard invasive clearance testing methods. GFRNMR will create an accessible, affordable, and reliable new diagnostic standard for patients.
The validation was performed in a retrospective study using US-based and European clinical data. The new test is based on numares ’ metabolomics approach: a combination of serum biomarkers, forming a metabolite constellation, analyzed by advanced nuclear magnetic resonance (NMR) spectroscopy and evaluated by numares ’ proprietary AI-driven diagnostic software. After training the test on US-based clinical data, 461 samples of international origin were used to validate the metabolite constellation.
“The outcome of this validation study surpasses the performance of the existing equations that are used to estimate kidney function,” says Dr. Volker Pfahlert, Chief Executive Officer of numares . “Our vision was to obtain a glomerular filtration rate (GFR) value from a simple blood sample that is comparable to the much more involved and invasive plasma clearance method. We are closer to the vision, as never before, to help identify and quantify reduced kidney function in patients with a more accurate, easy-to-access, and affordable diagnostic standard.”
Fifteen percent of U.S. adults (37 million people) are estimated to have chronic kidney disease*. Determining kidney function is important in many different medical conditions, e.g., patients with kidney transplants, late complications in diabetes management, patients with chronic congestive heart failure, or in dosing of nephrotoxic drugs.
The GFRNMR test will soon be further validated in additional clinical studies with ~1,500 patient samples comprised of additional clinical conditions and broader demographics. Based on these results, numares plans to submit the GFRNMR test for FDA Clearance in the first half 2021.
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs nuclear magnetic resonance (NMR) spectroscopy to create a “numaric” spectrum to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-MAWI-DNA-TECHNOLOGIES25.1.2021 15:02:12 CET | Press release
Mawi DNA’s Extractionless Sample Collection Technology Enables BioTech Africa Launch of Affordable COVID-19 Mass Testing Platform
KENUP-FOUNDATION25.1.2021 14:15:10 CET | Press release
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2
NY-ESTÉE-LAUDER25.1.2021 14:02:10 CET | Press release
The Estée Lauder Companies Announces Supply Chain Leadership Updates
NY-IWBI25.1.2021 14:02:10 CET | Press release
“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th U.S. Surgeon General Richard Carmona
MA-EVERBRIDGE25.1.2021 13:32:08 CET | Press release
Everbridge Awarded Statewide Vaccine Distribution Deployment Across West Virginia; Everbridge Software Enables Governments, Hospitals and Businesses to Coordinate Rapid Delivery and Communications of COVID-19 Vaccine
MA-EUSA-PHARMA25.1.2021 13:02:15 CET | Press release
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
CA-VELODYNE-LIDAR,-INC.25.1.2021 13:02:05 CET | Press release
Velodyne Lidar LIVE! Webinar Series Explores Autonomy in Smarter Cities, Caves, Airports and Disaster Response
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom